HOME >> BIOLOGY >> NEWS
AVELOX as effective as multi-dose combination therapy for intra-abdominal infections

Schering-Plough Corporation (NYSE: SGP) today reported that monotherapy with the once-daily, broad-spectrum antibiotic AVELOX (moxifloxacin HCl) was as effective and well tolerated as a standard multi-dose combination antibiotic regimen in the treatment of patients with complicated intra-abdominal infections (cIAI), according to results of a study involving 681 patients published in the current issue of the Annals of Surgery.(1) AVELOX, the only marketed fluoroquinolone antibiotic approved by the U.S. Food and Drug Administration (FDA) as monotherapy to treat cIAI, was shown to be effective at eradicating the most common bacteria that cause cIAI, including E. coli and B. fragilis.

In the study, patients who took 400 mg once daily of AVELOX intravenous (I.V.) followed by oral monotherapy achieved similar clinical cure rates (80 percent) at the test-of-cure visit (the primary efficacy endpoint) as patients who took a standard regimen of I.V. piperacillin-tazobactam followed by oral amoxicillin-clavulanate (78 percent).

Importantly, AVELOX demonstrated a significantly higher cure rate of 82 percent compared to 55 percent for the combination therapy among patients who acquired their cIAI in a hospital setting (including both mild-to-moderate and more severe hospital-acquired infections). Hospital-acquired infections are often caused by more resistant bacteria than community-acquired infections. Clinical cure rates for patients with community-acquired infections were similar between the two treatment groups.

The incidence of adverse events in the study due to any cause was similar for the two treatment groups, with the majority being mild or moderate in nature. The most common adverse events were nausea, hypokalemia, abdominal pain and constipation. The incidence of drug-related serious adverse events or premature discontinuation due to adverse events was similar for the two treatment groups.

"The results of this study are
'"/>


25-Jul-2006


Page: 1 2 3

Related biology news :

1. FDA approves AVELOX (moxifloxacin HCl) for treatment of complicated intra-abdominal infections
2. Smokeless tobacco more effective than cigarettes for delivering dangerous carcinogens into the body
3. Developing a more effective vaccine for tuberculosis
4. Cost-effective method for gene silencing is featured in Cold Spring Harbor Protocols
5. Implanon, Norplant and Jadelle are all effective contraceptives -- but side effects vary
6. High blood pressure medication strategy proves effective in Hispanic women
7. New compound effectively treats fungal infections
8. Northern forests less effective than tropical forests in reducing global warming
9. Cisplatin is more effective than carboplatin for treating nonsmall cell lung cancer
10. Scientists develop new drugs to fight colon and breast cancer more effectively
11. Avian influenza survivors antibodies effective at neutralising H5N1 strain

Post Your Comments:
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - ... partnership centralized around the incorporation of handyem,s HPC-150 ... diagnostic laboratory, the Mo-POD™. This unprecedented model of ... International Conference at the Pennsylvania ... from June 15 th to 18 th ...
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue guidance for ... at least 340 MSEK to that it will amount to ... growth and orders received the revenue guidance for 2015 is ... will exceed 1,500 MSEK to an updated guidance that revenue ... Due to receipt of orders of touch fingerprint sensors with ...
(Date:6/15/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... market, announces that its leading payment security technology, the Wocket® ... @ NYC June 18th. Digital Experience! @ NYC ... technology to over 300 of the top media covering the ... in New York City from 6:00 ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
(Date:6/29/2015)... Pharnext SAS today announced that data related to its ... Type 1A (CMT1A), is being presented in four posters and ... Biennial Meeting at the Quebec Congress Center in ... 2015. At Poster Viewing Session 4, four posters ... EDT: Poster 23: "A Meta-Analysis Of Randomized ...
(Date:6/29/2015)... June 29, 2015  MiMedx Group, Inc. (NASDAQ: ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of ... "Pete" Petit, has been awarded the Lifetime Achievement Award ... Program. The Entrepreneur Of The Year ...
(Date:6/29/2015)... --  For the seventh year running, Across Health conducted a ... maturity called the Multichannel Maturometer . The research ... fast enough. While it,s true that technology is indeed ... customers are increasingly "digital natives", pharma still lags behind ... Logo ...
(Date:6/26/2015)... ... June 26, 2015 , ... ... Agriculture (USDA), Grain Inspection, Packers and Stockyards Administration (GIPSA) awarded a five year ... in feed and grains utilizing Charm’s ROSA DONQ-FAST5 Test. This 5 minute quantitative ...
Breaking Biology Technology:Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx 2Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2
Cached News: